『Gene Therapy for Hemophilia: Dream or Reality?』のカバーアート

Gene Therapy for Hemophilia: Dream or Reality?

Gene Therapy for Hemophilia: Dream or Reality?

著者： Canadian Hemophilia Society
無料で聴く

このコンテンツについて

Gene therapy has remained a constant prospect in the sphere of hemophilia treatment. For over two decades and the question remained: Is this just a dream, or could it one day become a reality?

Hemophilia gene therapy has finally been approved.

David Page talks to hemophilia specialists that will dive deep into understanding how the treatment works, its significance in advancing treatment, and how a one time treatment could change a severe condition to a milder one.Though not a definitive cure, gene therapy for hemophilia has transformed the dream of a cure into a reality for the future.

David and his guests will provide exclusive insights into one of the most significant medical breakthroughs of our era.

© 2023 代替医療・補完医療 衛生・健康的な生活 身体的病い・疾患
エピソード
  • WEBINAR 2: [FR] Un Pas en Arrière, Deux Pas en Avant

    WEBINAR 2: [FR] Un Pas en Arrière, Deux Pas en Avant
    2025/02/19

    Le webinaire de la Société canadienne de l'hémophilie a abordé la thérapie génique pour les hémophiles. Dr. Jean St. Louis a expliqué les différences entre les injections de facteurs et la thérapie génique, en utilisant des vecteurs AAV pour introduire des gènes dans les cellules du foie. Il a détaillé les thérapies géniques approuvées par Santé Canada : MGX et Bec Vibes, soulignant leurs différences de dose et de taux d'échec. Les données à long terme montrent une réduction significative des saignements et une stabilité des niveaux de facteurs. Dr. David Page a discuté des défis de remboursement et de l'accès au traitement au Québec.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
    続きを読む 一部表示
    1 時間 3 分
  • WEBINAR 2: [EN] Hemophilia Gene Therapy: One Step Back, Two Steps Forward

    WEBINAR 2: [EN] Hemophilia Gene Therapy: One Step Back, Two Steps Forward
    2024/12/17

    The Canadian Hemophilia Society's December 4, 2024 webinar on hemophilia gene therapy featured the latest research and access updates. Dr. Roy Khalifé described how AAV vector gene therapy works in hemophilia A and B. He reported the latest clinical trial results for of Roctavian (hemophilia A) and Hemgenix and Beqvez (hemophilia B), noting annualized bleeding rates and levels of factor VIII and IX expression. Safety concerns included liver enzyme elevations and the need for short-term corticosteroids. David Page addressed regulatory hurdles, noting Health Canada's approvals of Hemgenix and Beqvez, CDA's positive reimbursement recommendations, but INESSS' negative reimbursement recommendations for Quebec. The discussion emphasized the need for long-term monitoring and equitable access across Canada.


    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
    続きを読む 一部表示
    1 時間 1 分
  • DEBATE: If gene therapy for hemophilia B were available in Canada tomorrow, would you want to receive it?

    DEBATE: If gene therapy for hemophilia B were available in Canada tomorrow, would you want to receive it?
    2024/06/05

    In this podcast, Elizabeth Vansant, Mark Pervan, Murray Milne and Mathieu Jackson, all individuals with severe hemophilia B, are asked to debate the question: “If gene therapy for hemophilia B were available in Canada tomorrow, would you want to receive it?”

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
    続きを読む 一部表示
    31 分
まだレビューはありません